Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Milou-Daniel Drici has a total of 132 co-authors. Here are the top co-authors by number of shared publications:

  • Alexandre Olivier Gérard

    Department of Clinical Pharmacology Université Côte d'Azur, University Hospital Centre of Nice Nice France

    20 shared publications
  • Fanny Rocher

    Department of Clinical Pharmacology, Université Côte d’Azur, University Hospital Centre of Nice, Nice, France

    18 shared publications
  • Diane Merino

    Department of Psychiatry, University Hospital of Nice, 06000 Nice, France

    16 shared publications
  • Alexandre Destere

    Department of Clinical Pharmacology, Université Côte d’Azur, University Hospital Centre of Nice, Nice, France

    10 shared publications
  • Alexandre O. Gérard

    Department of Nephrology-Dialysis-Transplantation, Université Côte d’Azur, University Hospital Centre of Nice, Nice, France

    10 shared publications
  • Delphine Viard

    Department of Clinical Pharmacology, Université Côte d’Azur, University Hospital Centre of Nice, Nice, France

    9 shared publications

Latest Publications

  • Open Access

    Mental health safety profile of CFTR modulators in pediatrics and adults: insights from the French pharmacovigilance database and from VigiBase

    by Diane A Merino, Samuel D Cohen, Nouha Ben Othman, Marie-Noëlle Osmont, Tessa Pietri, Sandrine Bergeron, Sophie Gautier, Fanny Rocher, Milou-Daniel Drici, Pierre-Régis Burgel, et al.

    Rationale: CFTR modulators (CFTRms) have transformed cystic fibrosis care, yet concern exists regarding their mental health safety profile. Objective: To provide further information, we conducted an analysis of CFTRm-related mental health disorders using two spontaneous pharmacovigilance reporting databases in real-world settings. Methods: We analyzed reports from the French Pharmacovigilance Database (FPD) and VigiBase, the WHO global individual case safety reports database. Reports recorded between 2012 and 2024 involving any CFTRm and psychiatric disorders were included. In VigiBase, we conducted a case-non case, disproportionality analysis using the Reporting Odds Ratio (ROR), overall and stratified by age group (pediatrics vs. adults) and by CFTRm type. This study was conducted in accordance with the STROBE and the READUS-PV guidelines. Results: In the FPD, 116 cases were analyzed. ELX/TEZ/IVA was suspected in 98% of cases and no single case was reported with ivacaftor alone. Sleep (61%), mood (37%), and anxiety disorders (27%) were the most frequently reported, with suicidal behaviors being infrequent, including 6 suicide attempts and no completed suicide. In VigiBase (n = 3,407), sleep disorders predominated in children, whereas mood and suicidality disorders were most frequent in adolescents. The median time to onset was 60 days (Q1-Q3: 12—150 days). Mental health disorders were disproportionately reported with CFTRms, particularly ELX/TEZ/IVA, while they were not with other combination therapies, compared to other drugs in the database. Disproportionality signals were slightly stronger in pediatrics than in adults. Conclusions: CFTRms, especially ELX/TEZ/IVA, are associated with increased reporting of mental health disorders, predominantly sleep and mood disorders. Pediatrics appear to be particularly affected. Prospective observational studies are warranted to confirm these findings and elucidate underlying pathophysiological mechanisms. Registration: OSF: mfyx3

  • Open Access

    Alice in wonderland syndrome: Down the rabbit hole of VigiBase®

    by Diane A. Merino, Alexandre O. Gérard, Faredj Cherikh, Thibaud Lavrut, Susanne Thümmler, Florence Askenazy, Milou-Daniel Drici, François Montastruc


  • Open Access

    Safety profile of belatacept in a real-life setting: disproportionality analysis of the WHO pharmacovigilance database

    by Alexandre O. Gérard, Diane Merino, Nouha Ben Othman, Alexandre Destere, Delphine Viard, Elliot Ewig, Fanny Rocher, Antoine Sicard, Milou-Daniel Drici

    Belatacept is a co-stimulation blocker used in kidney transplant recipients to prevent allograft rejection. Unlike calcineurin inhibitors, belatacept is non-nephrotoxic and may carry a lower risk of cardiovascular and metabolic complications. However, the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC) includes a broad range of adverse drug reactions (ADRs), mostly identified in small clinical trials with cyclosporine as a control, in patients exposed to other immunosuppressants. As real-world data on belatacept safety accumulate, a reassessment of its safety profile becomes essential. We analyzed pharmacovigilance data from VigiBase®, the World Health Organization global safety database, to explore discrepancies between postmarketing ADR reports and the belatacept Summary of Product Characteristics (SmPC). A disproportionality analysis was performed using the Information Component, a Bayesian metric, to identify potential pharmacovigilance signals. We retrieved 2795 reports involving belatacept, including 424 (15.2%) fatal cases. The disproportionality analysis highlighted 51 potential signals that were not explicitly listed in the SmPC, such as Clostridium difficile infection, hepatitis B reactivation, and hemophagocytic lymphohistiocytosis. Conversely, 47 (33.1%) of the 142 ADRs classified as “common” or “very common” in the SmPC, such as Cushing’s syndrome or depression, had fewer than three reports in VigiBase®. This study highlights discrepancies between the belatacept SmPC and real-world pharmacovigilance data. Several labeled ADRs were not reported frequently in VigiBase®, suggesting that they may be less commonly observed in real-world settings. Others, particularly infections, warrant further scrutiny. Yet, these findings should be interpreted with caution due to the inherent limitations of pharmacovigilance data, including underreporting, reporting bias, and residual confounding. Pharmacovigilance approaches generate signals, but cannot definitively establish or exclude a causal relationship. Nonetheless, these findings suggest the need for periodic reassessment of belatacept’s safety profile to ensure accurate and clinically relevant information for healthcare providers.


  • Open Access

    Evaluating and leveraging large language models in clinical pharmacology and therapeutics assessment: From exam takers to exam shapers

    by Alexandre O. Gérard, Diane Merino, Marc Labriffe, Fanny Rocher, Delphine Viard, Laurence Zemori, Thibaud Lavrut, Erik M. Donker, Joost D. Piët, Jean‐Paul Fournier, et al.

    Aims: In medical education, the ability of large language models (LLMs) to match human performance raises questions about their potential as educational tools. This study evaluates LLMs' performance on Clinical Pharmacology and Therapeutics (CPT) exams, comparing their results to medical students and exploring their ability to identify poorly formulated multiple‐choice questions (MCQs).Methods: ChatGPT‐4 Omni, Gemini Advanced, Le Chat and DeepSeek R1 were tested on local CPT exams (third year of bachelor's degree, first/second year of master's degree) and the European Prescribing Exam (EuroPE+). The exams included MCQs and open‐ended questions assessing knowledge and prescribing skills. LLM results were analysed using the same scoring system as students. A confusion matrix was used to evaluate the ability of ChatGPT and Gemini to identify ambiguous/erroneous MCQs.Results: LLMs achieved comparable or superior results to medical students across all levels. For local exams, LLMs outperformed M1 students and matched L3 and M2 students. In EuroPE+, LLMs significantly outperformed students in both the knowledge and prescribing skills sections. All LLM errors in EuroPE+ were genuine (100%), whereas local exam errors were frequently due to ambiguities or correction flaws (24.3%). When both ChatGPT and Gemini provided the same incorrect answer to an MCQ, the specificity for detecting ambiguous questions was 92.9%, with a negative predictive value of 85.5%.Conclusion: LLMs demonstrate capabilities comparable to or exceeding medical students in CPT exams. Their ability to flag potentially flawed MCQs highlights their value not only as educational tools but also as quality control instruments in exam preparation.


  • Open Access

    PDL1 inhibitors may be associated with a lower risk of allograft rejection than PD1 and CTLA4 inhibitors: analysis of the WHO pharmacovigilance database

    by Alexandre O. Gérard, Diane Merino, Jonathan Benzaquen, Alexandre Destere, Delphine Borchiellini, Clément Gosset, Fanny Rocher, Marine Andreani, Charles-Hugo Marquette, Henri Montaudié, et al.

    Background: Transplant recipients face increased cancer mortality due to immunosuppressive treatments. Immune checkpoint inhibitors (ICI) have improved survival rates, but data on the use of these agents in transplant recipients is scarce. ICI may trigger allograft rejection, but the absolute risk of AR between the different ICI classes remains to be defined.Methods: VigiBase® (WHO’s pharmacovigilance database) was queried for reports of AR involving CTLA4, PD1, or PDL1 inhibitors. Disproportionality analysis compares the proportion of reports with a specific adverse drug reaction (ADR) and a given drug to the proportion of reports with the same ADR and other drugs. A lower 95% confidence interval for the Information Component (IC) >0 suggests a signal. The comparative Reporting Odds Ratios (ROR) for AR, between PD1 and PDL1 inhibitors, was calculated.Results: We gathered 159 AR involving an ICI, especially nivolumab (73, 45.9%), mostly affecting kidneys (87, 54.7%). Median time to onset: 28 days. Fatal outcome: 36 reports (22.6%). ICI were significantly associated with AR: IC=1.7 [1.4;1.9]. Specifically, PD1 inhibitors yielded an IC of 2.0 [1.7;2.2] (152 reports observed compared to 38 expected). By contrast, the IC of PDL1 inhibitors was negative: -2.6 [-6.4;-1.0] (1 observed, 9 expected). The comparative ROR of PD1 compared to PDL1 inhibitors was 33.7 [4.7;240.9] (p=0.0005).Conclusions: We confirm the association between ICI treatment and AR. Notably, PDL1 inhibitors showed surprisingly low AR reports compared to CTLA4 and PD1 inhibitors. Further prospective studies are warranted to confirm whether PDL1 inhibitors indeed reduce AR risk compared to other ICI.


  • Polyintoxication with cenobamate, perampanel, and carbamazepine: A complex case report

    by Alexandre Destere, Alexandre O. Gérard, Diane Merino, Elliot Ewig, Fanny Rocher, Nouha Ben Othmann, Benjamin Hennart, Jean Dellamonica, Hervé Hyvernat, Milou-Daniel Drici


  • Open Access

    Lipschütz ulcer following first dose of COVID ‐19 tozinameran vaccine: Report of a case and review of a World Health Organization pharmacovigilance database

    by Elliot Ewig, Nouha Ben Othman, Delphine Viard, Pierre‐Alexis Gauci, Fanny Rocher, Milou‐Daniel Drici

    Lipschütz ulcer (LU) is a condition known for painful vulvar ulcers, typically affecting young women and often linked to infectious agents. Recent reports have indicated a potential connection between LU and COVID‐19 vaccination, particularly after the second or booster doses. This study presents a case of LU following the first dose of tozinameran in a young woman who had a previous SARS‐CoV‐2 infection and investigates similar cases globally. An 18‐year‐old woman experienced vulvar pain and ulcers 2‐days after her initial COVID‐19 vaccine dose. After ruling out infections through serological tests, a diagnosis of LU was made, and her symptoms resolved after 10 days. A literature search and VigiBase® analysis revealed 11 cases of LU following COVID‐19 vaccination, and 519 vulvovaginal ulcer cases associated with these vaccines were identified in Vigibase®, with a median onset of 2 days. Most LU cases occurred after the second dose or booster shots. The primary hypothesis for this association is a type 3 hypersensitivity reaction mediated by immune complexes, possibly triggered by prior exposure, as many cases occurred after the second dose. Interestingly, the presented case suggests that prior COVID‐19 infection could serve as sensitization. In conclusion, this study highlights the potential occurrence of LU after the initial COVID‐19 vaccine dose in young patients with prior COVID‐19 infection. While the risk of recurrence after subsequent vaccinations or infections remains uncertain, the benefits of vaccination outweigh the risks. Clinicians and patients should be aware of this potential issue to make informed decisions regarding vaccination.


  • Open Access

    Dental Adverse Effects of Anti-CD20 Therapies

    by Hélène Bartak, Tasnim Fareh, Nouha Ben Othman, Delphine Viard, Mikael Cohen, Fanny Rocher, Elliot Ewig, Milou-Daniel Drici, Christine Lebrun-Frenay

    Introduction Over the past few years, anti-CD20 therapies like rituximab, ocrelizumab or ofatumumab have seen an increase in interest in the treatment of neurological autoimmune disorders such as multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), or resistant forms of generalized myasthenia gravis (MG). They are generally well-tolerated, but recent reports have highlighted severe dental disorders in patients undergoing anti-CD20 therapies. The aim was to describe a series of cases and to compare with the available scientific literature. Methods We reviewed 6 patient cases with dental disorders during anti-CD20 therapy that were reported to the pharmacovigilance center. A disproportionality analysis was also conducted on Vigibase® for each anti-CD20 and each adverse effect described in the cases. Results Six cases of dental and gingival conditions in relatively young patients were reported (median age: 40.5 years old [min: 34; max: 79]). Oral conditions were developed in four patients with MS treated with ocrelizumab and in two patients receiving rituximab (one patient with MG and one with NMOSD). The onset of oral conditions ranged from 10 days to 2 years after treatment initiation. Notably, all patients treated with ocrelizumab experienced gingival recession. Various dental pathologies were observed, including tooth loss, dental pain, caries, brittle teeth, dental fractures, dental abscesses, and periodontitis. Analysis of Vigibase® revealed 284 worldwide cases of dental and gingival conditions under ocrelizumab, 386 cases under rituximab, and 80 under ofatumumab. Significant associations were found between these therapies and dental pathologies, particularly tooth abscesses and infections. Conclusion To our knowledge, this is the first case series reporting dental conditions developed in patients long-term treated with anti-CD20 treatments. This issue, literature data, and Vigilyze® analysis might be considered a safety signal that necessitates being confirmed with more robust data, such as a retrospective study with a control group. Meanwhile, proactive measures are essential like frequent dental checkups and dental hygienic measures to prevent oral health problems associated with anti-CD20 therapies.


  • Open Access

    Cardiac and metabolic safety profile of antipsychotics in youths: A WHO safety database analysis

    by Diane Merino, Alexandre O. Gérard, Alexandre Destere, Haitam Saidessalam, Florence Askenazy, François Montastruc, Milou-Daniel Drici, Susanne Thümmler


  • An artificial intelligence algorithm for co‐clustering to help in pharmacovigilance before and during the COVID‐19 pandemic

    by Alexandre Destere, Giulia Marchello, Diane Merino, Nouha Ben Othman, Alexandre O. Gérard, Thibaud Lavrut, Delphine Viard, Fanny Rocher, Marco Corneli, Charles Bouveyron, et al.

    Aims: Monitoring drug safety in real‐world settings is the primary aim of pharmacovigilance. Frequent adverse drug reactions (ADRs) are usually identified during drug development. Rare ones are mostly characterized through post‐marketing scrutiny, increasingly with the use of data mining and disproportionality approaches, which lead to new drug safety signals. Nonetheless, waves of excessive numbers of reports, often stirred up by social media, may overwhelm and distort this process, as observed recently with levothyroxine or COVID‐19 vaccines. As human resources become rarer in the field of pharmacovigilance, we aimed to evaluate the performance of an unsupervised co‐clustering method to help the monitoring of drug safety.Methods: A dynamic latent block model (dLBM), based on a time‐dependent co‐clustering generative method, was used to summarize all regional ADR reports (n = 45 269) issued between 1 January 2012 and 28 February 2022. After analysis of their intra and extra interrelationships, all reports were grouped into different cluster types (time, drug, ADR).Results: Our model clustered all reports in 10 time, 10 ADR and 9 drug collections. Based on such clustering, three prominent societal problems were detected, subsequent to public health concerns about drug safety, including a prominent media hype about the perceived safety of COVID‐19 vaccines. The dLBM also highlighted some specific drug–ADR relationships, such as the association between antiplatelets, anticoagulants and bleeding.Conclusions: Co‐clustering and dLBM appear as promising tools to explore large pharmacovigilance databases. They allow, ‘unsupervisedly’, the detection, exploration and strengthening of safety signals, facilitating the analysis of massive upsurges of reports.